Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

NCT03126331 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Case Comprehensive Cancer Center